AdaptVac's virus like particle (VLP)*2 technology, which has achieved a high level of safety and effectiveness, is drawing significant attention as a candidate vaccine that could effectively protect the human body from COVID-19 infection.
AGC Biologics, a CDMO subsidiary of AGC, utilizes mammalian and microbial cells and in production to provide a variety of high value-added services that range from process development to upscaling, clinical trials, and commercial drug manufacturing. The company was selected as a manufacturing partner for COVID-19 vaccines in recognition of its high-level quality and services.
*1 CDMO: Contract Development & Manufacturing Organization. A company which is contracted or acts on behalf of another company to handle product manufacturing as well as the development manufacturing methods.
*2 Virus like particle (VLP): Because VLPs are similar in structure to viruses, they are anticipated to provide strong immunity as vaccines. Due also to their excellent safety in preventing virus proliferation in the body, they are attracting significant interest as a promising vaccine technology.
AdaptVac is a joint venture between 'ExperS2ion Biotech' and University of Copenhagen's spin-out venture 'NextGen Vaccines ApS', whose aim is to develop therapeutic drugs and vaccines for treating and preventing infectious diseases, cancer and immune disorders. Visit the URL below for more details.